Document is current

Any future updates will be listed below

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Crossref DOI link: https://doi.org/10.1186/s40942-016-0058-3

Published Online: 2017-02-13

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark